Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

22q11.2 Deletion Syndrome Clinical Trial

Official title:
A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)

Status Completed

Clinical Trial Summary

This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02895906
Study type	Interventional
Source	Cerecor Inc
Contact
Status	Completed
Phase	Phase 1
Start date	November 28, 2016
Completion date	April 20, 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04639960` - Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome	N/A
Recruiting	`NCT04373226` - Arithmetic Abilities in Children With 22q11.2DS	N/A
Completed	`NCT01781923` - Cognitive Remediation in 22q11DS	N/A
Terminated	`NCT03284060` - Social Cognition Training and Cognitive Remediation	N/A
Recruiting	`NCT04639388` - Understanding of Psychotic Disorders in Children With 22q11.2DS	N/A
Completed	`NCT00916955` - Genetic Modifiers for 22q11.2 Syndrome
Recruiting	`NCT05924347` - Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
Recruiting	`NCT00556530` - Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
Completed	`NCT02460328` - Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome	N/A
Completed	`NCT04647500` - Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome	N/A